Zai Lab (ZLAB )and Innoviva (INVA) announced that China’s National Medical Products Administration, or NMPA, has approved Zai Lab’s New Drug Application (NDA) for Xacduro for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
